KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read More
An "off-the-shelf" therapy that can be used immediately, rather than one that needs to be manufactured individually for each patient (such as chimeric antigen receptor T (CAR-T) cell therapies) and can be a life-saving proposition for patients facing difficult-to-treat diseases, such as many cancers. The promise of bispecific antibodies (bsAbs) comes from their “off-the-shelf” nature and their ability to recognize multiple targets simultaneously. While many of the bsAbs in development fundamentally maintain the heavy and light chain structure of standard antibodies, advances in protein engineering have allowed for development of smaller versions such as BiTEs and DARTs and for more complex versions with extra binding domains appended to the heavy and/or light chains of the antibodies.
For a manufacturing platform to be truly effective at making bsAbs, it should have three key features:
The Selexis’ SUREtechnology Platform™ provides a modular approach to cell line development that not only provides top cell line productivity levels in the industry, but also has sophisticated capabilities to address the myriad of challenges associated with producing complex difficult-to-express proteins, which bsAbs can be. To address the three key capabilities required for bsAbs production, the SUREtechnology Platform™ has:
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.